Manufacturing Capacity Petrovax operates a modern manufacturing complex in the Moscow region with API synthesis and sterile/non-sterile production, compliant with EAEU and EU GMP standards. The annual capacity is 160 million doses, enabling scalable supply for vaccines and biopharma products. This makes the company a strong partner for contract manufacturing, toll manufacturing, and supply agreements in EAEU and EU markets.

Strategic Partnerships The company is one of Russia’s largest exporters of original medicines and vaccines, with existing supply to EAEU and EU countries. It maintains partnerships with major global players including Pfizer, Abbott, ISU ABXIS, Adimmune, and Hengrui. These relationships signal opportunities for licensing, co-development, or distribution agreements with international partners.

R&D Capabilities Petrovax owns an in-house R&D center for pre-clinical studies and holds patents for molecules and manufacturing technologies in Russia and abroad, enabling a full cycle of drug development and technology licensing. This supports opportunities for tech transfer, collaboration on novel formulations, and expediting go-to-market for new therapies.

Therapeutic Focus The development strategy targets vaccines and medicines for infectious, oncological, and orphan diseases, addressing high-priority public health needs and potential government procurement streams. This alignment creates sales opportunities for vaccine programs, specialty medicines, and therapies for underserved patient populations.

Growth Readiness With decades of experience and a broad export footprint, Petrovax shows growth readiness and a track record of collaboration with multinational partners. Its digital stack and manufacturing excellence support scalable partnering models, including contract manufacturing, joint ventures, licensing, and co-marketing initiatives in global markets.